Monopar Therapeutics (MNPR) shares are experiencing a sharp decline on Friday after gaining on Thursday, following the company’s licensing agreement with Alexion, AstraZeneca Rare Disease for ALXN-1840, a potential treatment for Wilson disease. While the drug has shown promise in a Phase 3 clinical trial, its development was previously halted due to Phase 2 data and regulatory concerns. Monopar will now lead the development and commercialization efforts.